DBV Technologies (NASDAQ:DBVT) Shares Climb 4.9% – Still a Buy?

Posted by Stanley Muller on Sep 30th, 2026

Shares of DBV Technologies S.A. (NASDAQ:DBVT – Get Free Report) rose 4.9% during mid-day trading on Monday. The stock traded as high as $12.00 and last traded at $12.13. 281,502 shares were traded during mid-day trading, a decline of 6% from the average session volume of 300,963 shares. The stock had previously closed at $11.56.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Wall Street Zen lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Citizens Jmp increased their price objective on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Tuesday, June 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of DBV Technologies in a report on Thursday, September 10th. Finally, Citigroup restated a “market outperform” rating on shares of DBV Technologies in a research report on Wednesday. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $48.50.

Get Our Latest Stock Report on DBVT

DBV Technologies Stock Down 0.8%

The firm has a 50 day moving average price of $13.40 and a 200 day moving average price of $16.69. The stock has a market cap of $726.26 million, a P/E ratio of -3.29 and a beta of -0.95.

Institutional Investors Weigh In On DBV Technologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vivo Capital LLC boosted its position in shares of DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after purchasing an additional 205,943 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of DBV Technologies during the 1st quarter valued at $21,159,000. Perceptive Advisors LLC bought a new stake in shares of DBV Technologies during the 1st quarter valued at $20,146,000. Atika Capital Management LLC lifted its stake in shares of DBV Technologies by 31.1% during the 1st quarter. Atika Capital Management LLC now owns 271,300 shares of the company’s stock valued at $5,667,000 after buying an additional 64,419 shares in the last quarter. Finally, Elmind Capital LP purchased a new position in shares of DBV Technologies during the 1st quarter valued at $5,536,000. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

(Get Free Report)

DBV Technologies SA is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies’ primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.